Tempest Therapeutics, Inc. Common Stock (TPST)

Price$1.27

Value ScoreF

Growth ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-68.24%

Price vs S&P 500 (4W)-36.17%

VGM Score20.70

Market Capitalization$18.80M

All Metrics

Book Value / Share (Quarterly)$0.06

P/TBV (Annual)4.17x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.84

Price vs S&P 500 (YTD)-63.91%

Gross Margin (TTM)-46.67%

Net Profit Margin (TTM)-9760.00%

EPS (TTM)$-6.21

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-6.21

EPS (Annual)$-6.33

ROI (Annual)-393.85%

Gross Margin (Annual)-166.67%

Cash / Share (Quarterly)$0.13

Revenue Growth QoQ (YoY)0.00%

ROA (Last FY)-155.11%

Revenue Growth TTM (YoY)-6.25%

EBITD / Share (TTM)$-7.16

ROE (5Y Avg)-199.70%

Operating Margin (TTM)-10020.00%

Cash Flow / Share (Annual)$-5.44

P/B Ratio22.88x

P/B Ratio (Quarterly)28.62x

Net Income / Employee (Annual)$-6,565,500

EV / Revenue (TTM)56.67x

Net Interest Coverage (TTM)-87.30x

ROA (TTM)-248.79%

EPS Incl Extra (Annual)$-6.33

Current Ratio (Annual)2.50x

Quick Ratio (Quarterly)0.55x

3-Month Avg Trading Volume0.19M

52-Week Price Return-84.00%

Revenue / Employee (TTM)$75,000

Tangible BV / Share (Quarterly)$-0.08

P/S Ratio (Annual)62.68x

Asset Turnover (Annual)0.00x

52-Week High$12.23

EPS Excl Extra (Annual)$-6.33

CapEx CAGR (5Y)1.69%

Tangible BV CAGR (5Y)-22.38%

26-Week Price Return-60.31%

Quick Ratio (Annual)2.43x

13-Week Price Return-45.02%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.74x

Enterprise Value$17.00M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-44.36%

Revenue / Employee (Annual)$75,000

Pretax Margin (Annual)-16970.00%

Cash / Share (Annual)$1.56

3-Month Return Std Dev108.99%

Net Income / Employee (TTM)$-10,774,500

ROE (Last FY)-393.85%

Net Interest Coverage (Annual)-2110.20x

EPS Basic Excl Extra (Annual)$-6.33

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-6.21

ROI (TTM)-729.89%

P/S Ratio (TTM)62.68x

Revenue / Share (Annual)$1.88

Tangible BV / Share (Annual)$1.72

Price vs S&P 500 (52W)-108.37%

Year-to-Date Return-55.75%

5-Day Price Return-12.41%

EPS Normalized (Annual)$-6.33

ROA (5Y Avg)-85.85%

Net Profit Margin (Annual)-16993.33%

Month-to-Date Return-16.99%

Cash Flow / Share (TTM)$-2.20

EBITD / Share (Annual)$-6.34

Operating Margin (Annual)-16870.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-163.53%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-6.21

P/B Ratio (Annual)2.12x

Pretax Margin (TTM)-9746.67%

Book Value / Share (Annual)$1.35

Price vs S&P 500 (13W)-53.28%

Beta-1.67x

Revenue / Share (TTM)$1.88

ROE (TTM)-729.89%

52-Week Low$1.23

vGradeF

gGradeD

mGradeF

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-2.53est. -0.29

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TPSTTempest Therapeutics, Inc. Common Stock	F	D	F	$1.27
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Tempest Therapeutics is a late-stage biotechnology company developing small molecule cancer therapeutics designed to directly eliminate tumor cells while activating anti-tumor immunity. The company's clinical-stage pipeline includes TPST-1120 and TPST-1495, targeting distinct mechanisms in oncology.